Alexion Pharmaceuticals, Inc.

Dayang Wu

Russell P Rother

Katherine S Bowdish

Anke Kretz-Rommel

Jeremy P Springhorn

Susan Faas McKnight

Susan Faas Mcknight

Kathrine S Bowdish

Susan Mcknight Faas

This application provides methods and compositions for modulating and/or depleting CD200 positive cells.

Antibodies to OX-2/CD200 and uses thereof

Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments 5 contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and 10 nonhuman CDRs.

Hybrid antibodies

Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.

Growing community of inventors

Cheshire, CT, United States of America

Dayang Wu